F9056

Anti-FRAT1 antibody produced in rabbit

~1.5 mg/mL, affinity isolated antibody, buffered aqueous solution

• Synonim(y): Anti-Frequently rearranged in advanced T-cell lymphomas, Anti-GBP, Anti-GSK-3 binding protein
• Kod UNSPSC: 12352203
• NACRES: NA.41

Właściwości

• pochodzenie biologiczne: rabbit
• białko sprzężone: unconjugated
• forma przeciwciała: affinity isolated antibody
• rodzaj przeciwciała: primary antibodies
• klon: polyclonal
• Postać: buffered aqueous solution
• masa cząsteczkowa: antigen ~29 kDa
• reaktywność gatunkowa: human
• opakowanie: antibody small pack of 25 μL
• rozszerzona walidacja: recombinant expression; Learn more about Antibody Enhanced Validation
• stężenie: ~1.5 mg/mL
• metody: western blot: 1-2 μg/mL using using rat liver extract (S1 fraction) and a HEK-293T cell lysate expressing human FRAT1.
• numer dostępu UniProt: Q92837
• Warunki transportu: dry ice
• temp. przechowywania: −20°C
• docelowa modyfikacja potranslacyjna: unmodified
• informacje o genach: human ... FRAT1(10023)

Opis

Opis ogólny

FRAT1 (frequently rearranged in advanced T-cell lymphomas-1) is a GSK3β binding protein consisting of a conserved GSK3β interacting domain. In human two FRAT genes have been identified, FRAT1 and FRAT2 whereas FRAT1-3 have been identified in mouse.

Zastosowanie

Anti-FRAT1 antibody produced in rabbit is suitable for western blot at a concentration of 1-2μg/mL using rat liver extract (S1 fraction) and a HEK-293T cell lysate expressing human FRAT1.

Działania biochem./fizjol.

By inhibiting GSK-3-mediated phosphorylation of β-catenin, FRAT1 plays a major role in the wnt-signaling pathway. During binding to the GSKβ3, it competes with axin, and thus displacing GSK3β from the axin-β-catenin complex. In the canonical wnt signaling pathway, FRAT1 acts more efficiently than FRAT2. FRAT1 has correlation with clinicopathologic features. It has been reported that in several human malignant tumors, FRAT is overexpressed. It′s upregulated expression have been found in several human cancer lines such as gastric cancers and esophageal squamous cell carcinoma (ESCC).

Postać fizyczna

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Oświadczenie o zrzeczeniu się odpowiedzialności

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

This page may contain text that has been machine translated.